Atropine Sulfate (atropine sulfate)
Ophthalmic Cycloplegics/Mydriatics Ophthalmic (Eye) Drops
Last reviewed · Source: First Databank (FDB) drug data
Overview
Atropine (dl-hyoscyamine), a naturally occurring tertiary amine antimuscarinic, is a mydriatic and cycloplegic.
Atropine sulfate ophthalmic preparations are used to produce mydriasis and cycloplegia for examination of the retina and optic disk and accurate measurement of refractive errors. However, because of the long duration of action of the drug, it is seldom, if ever, used for cycloplegic refraction in adults. In rare cases, topical ophthalmic atropine use may be necessary to achieve maximal cycloplegia in pediatric patients, but cyclopentolate is more frequently used.
Generic name: atropine sulfate
Pronunciation: (AT-roe-peen)
Drug class: Ophthalmic Cycloplegics/Mydriatics
Therapeutic class: Ophthalmic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Atropine Sulfate
Indications
The following indications are listed for Atropine Sulfate:
- Cycloplegia
- Mydriasis
- Penalization Therapy For Unilateral Amblyopia
Dosing
To produce mydriasis and cycloplegia for refraction in adults, 1 drop of a 1% solution may be instilled onto the eye(s) 1 hour before the procedure. In children, the usual dosage for cycloplegic refraction is 1-2 drops of a 0.5% solution instilled onto the eye(s) twice daily for 1-3 days before the procedure (the 0.5% solution is no longer commercially available in the US). Alternatively, to produce mydriasis and cycloplegia for refraction in adults, 0.3-0.5 cm of a 1% ointment may be placed into the conjunctival sac 1-3 times daily. In children, the usual dosage for cycloplegic refraction is 0.3 cm of a 1% ointment placed into the conjunctival sac 3 times daily for 1-3 days before the procedure. If the ointment is used for refraction, the drug should be applied several hours before the procedure, since it may impair corneal transparency and prevent accurate measurement of refractive errors.
For pupillary dilation in the treatment of acute inflammatory conditions of the iris and uveal tract in adults (i.e., iridocyclitis, uveitis), 1 or 2 drops of a 0.5 or 1% solution may be instilled onto the eye(s) up to 4 times daily. In children, the usual dosage for the treatment of uveitis is 1 or 2 drops of a 0.5% solution up to 3 times daily. Alternatively, for pupillary dilation in the treatment of acute inflammatory conditions of the iris and uveal tract in adults and children, 0.3-0.5 cm of a 1% ointment may be placed into the conjunctival sac up to 3 times daily.
Atropine sulfate is applied topically to the eye in the form of an ophthalmic ointment or solution. To avoid excessive systemic absorption, finger pressure should be applied on the lacrimal sac during and for 1-2 minutes following topical administration of the solution or ointment. Care should be taken to avoid contamination of the ointment tube and solution container.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- Hypertension
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Acute cognitive impairment
- Anticholinergic toxicity
- Ataxia
- Behavioral disorders
- Dizziness
- Drowsy
- Dry skin
- Fatigue
- Fever
- Flushing
- Hallucinations
- Skin rash
- Slurred speech
- Tachycardia
- Unsteady gait
- Xerostomia
Less Frequent
- Blurred vision
- Eyelid edema
- Ocular irritation
- Photophobia
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Mydriasis | ||
| Z01.0 | ICD10CM | Encounter for examination of eyes and vision |
| Z01.00 | ICD10CM | Encounter for examination of eyes and vision without abnormal findings |
| Z01.01 | ICD10CM | Encounter for examination of eyes and vision with abnormal findings |
| Penalization therapy for unilateral amblyopia | ||
| H53.0 | ICD10CM | Amblyopia ex anopsia |
| H53.00 | ICD10CM | Unspecified amblyopia |
| H53.001 | ICD10CM | Unspecified amblyopia, right eye |
| H53.002 | ICD10CM | Unspecified amblyopia, left eye |
| H53.009 | ICD10CM | Unspecified amblyopia, unspecified eye |
| H53.01 | ICD10CM | Deprivation amblyopia |
| H53.011 | ICD10CM | Deprivation amblyopia, right eye |
| H53.012 | ICD10CM | Deprivation amblyopia, left eye |
| H53.019 | ICD10CM | Deprivation amblyopia, unspecified eye |
| H53.02 | ICD10CM | Refractive amblyopia |
| H53.021 | ICD10CM | Refractive amblyopia, right eye |
| H53.022 | ICD10CM | Refractive amblyopia, left eye |
| H53.029 | ICD10CM | Refractive amblyopia, unspecified eye |
| H53.03 | ICD10CM | Strabismic amblyopia |
| H53.031 | ICD10CM | Strabismic amblyopia, right eye |
| H53.032 | ICD10CM | Strabismic amblyopia, left eye |
| H53.039 | ICD10CM | Strabismic amblyopia, unspecified eye |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.